“And we now have an asset that is broadly applicable across a number of serious neuropsychiatric diseases.”
→ Read the source episode
LB102 shows positive clinical trial results in at least two additional neuropsychiatric indications (bipolar depression and adjunctive MDD) beyond schizophrenia.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.